Publicacions en què col·labora amb Cristina Hurtado Rudi (16)

2024

  1. CALR but Not JAK2 Mutations Are Associated with an Overexpression of Retinoid X Receptor Alpha in Essential Thrombocythemia

    Cancers, Vol. 16, Núm. 8

2023

  1. Monitoring Caenorhabditis elegans molting in a conventional luminometer

    MethodsX, Vol. 10

  2. Optimizing simple calreticulin upregulation strategies in Caenorhabditis elegans

    Biology Methods and Protocols, Vol. 8, Núm. 1

  3. Transcriptomic Analysis Reveals JAK2/MPL-Independent Effects of Calreticulin Mutations in a C. elegans Model

    Cells, Vol. 12, Núm. 1

2018

  1. Borago officinalis seed oil (BSO), a natural source of omega-6 fatty acids, attenuates fat accumulation by activating peroxisomal beta-oxidation both in C. elegans and in diet-induced obese rats

    Food and Function, Vol. 9, Núm. 8, pp. 4340-4351

  2. Dihomo-gamma-linolenic acid induces fat loss in: C. Elegans in an omega-3-independent manner by promoting peroxisomal fatty acid β-oxidation

    Food and Function, Vol. 9, Núm. 3, pp. 1621-1637

2017

  1. p.Y317H is a new JAK2 gain-of-function mutation affecting the FERM domain in a myelofibrosis patient with CALR mutation

    Haematologica

2014

  1. A simple approach for classifying new mutations as somatic or germinal in DNA samples lacking paired tissue

    BioTechniques, Vol. 56, Núm. 6, pp. 327-329

2013

  1. A new KRT16 mutation associated with a phenotype of pachyonychia congenita

    Experimental Dermatology

  2. CBL RING finger deletions are common in core-binding factor acute myeloid leukemias

    Leukemia and Lymphoma

2012

  1. A meta-analysis of TET2 mutations shows a distinct distribution pattern in de novo acute myeloid leukemia and chronic myelomonocytic leukemia

    Leukemia and Lymphoma

  2. CBL mutations in myeloproliferative neoplasms are also found in the gene's proline-rich domain and in patients with the V617FJAK2

    Haematologica, Vol. 97, Núm. 8, pp. 1234-1241

2011

  1. LNK can also be mutated outside PH and SH2 domains in myeloproliferative neoplasms with and without V617FJAK2 mutation

    Leukemia Research, Vol. 35, Núm. 11, pp. 1537-1539

2010

  1. A new potential oncogenic mutation in the FERM domain of JAK2 in BCR/ABL1-negative and V617F-negative chronic myeloproliferative neoplasms revealed by a comprehensive screening of 17 tyrosine kinase coding genes

    Cancer Genetics and Cytogenetics, Vol. 199, Núm. 1, pp. 1-8

  2. Quantification of PDGFRA alternative transcripts improves the screening for XPDGFRA fusions by reverse transcriptase-polymerase chain reaction

    Leukemia and Lymphoma, Vol. 51, Núm. 9, pp. 1720-1726

2008

  1. Low frequency of JAK2 exon 12 mutations in classic and atypical CMPDs

    Leukemia Research